G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage.

Pena, Nicholas; Richbourg, Tara; Gonzalez-Hunt, Claudia P; Qi, Rui; Wren, Paul; Barlow, Carrolee; Shanks, Natalie F; Carlisle, Holly J; Sanders, Laurie H

Pena, Nicholas; Richbourg, Tara; Gonzalez-Hunt, Claudia P; Qi, Rui; Wren, Paul; Barlow, Carrolee; Shanks, Natalie F; Carlisle, Holly J; Sanders, Laurie H.

Afiliação

Pena N; Departments of Neurology and Pathology, Duke University School of Medicine, Durham, NC, 27710, USA.
Richbourg T; Duke Center for Neurodegeneration and Neurotherapeutics, Duke University, Durham, NC, USA.
Gonzalez-Hunt CP; Departments of Neurology and Pathology, Duke University School of Medicine, Durham, NC, 27710, USA.
Qi R; Duke Center for Neurodegeneration and Neurotherapeutics, Duke University, Durham, NC, USA.
Wren P; Departments of Neurology and Pathology, Duke University School of Medicine, Durham, NC, 27710, USA.
Barlow C; Duke Center for Neurodegeneration and Neurotherapeutics, Duke University, Durham, NC, USA.
Shanks NF; Departments of Neurology and Pathology, Duke University School of Medicine, Durham, NC, 27710, USA.
Carlisle HJ; Duke Center for Neurodegeneration and Neurotherapeutics, Duke University, Durham, NC, USA.
Sanders LH; ESCAPE Bio, Inc., South San Francisco, CA, 94080, USA.

NPJ Parkinsons Dis ; 10(1): 49, 2024 Mar 01.

Article em En | MEDLINE | ID: mdl-38429321

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article